


Quantum X Labs Inc. (QXL)

Nasdaq; business equipment; SIC 7372, Services-Prepackaged Software; CIK 0000797542

Quantum X Labs Inc. QXL; business equipment		
Grade	None 4 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$10.8M	
Standard universe	inside revenue above \$1M and assets above \$10M	
Warnings	late filer, thin data not computable: dilution, distress	
Inputs computable	4 of 14	
Graded from	filings received through Mar 27, 2026 196 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026	
Last close	\$4.07 2026-10-08; market equity \$87.8M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Inc. (the "Registrant", "Viewbix" or the "Company") was incorporated in the State of Delaware on August 16, 1985, under a predecessor name, The InFerGene Company ("InFerGene Company"). On August 25, 1995, a wholly owned subsidiary of InFerGene Company merged with Zaxis International, Inc., an Ohio corporation, which following such merger, the surviving entity, InFerGene Company, changed its name to Zaxis International, Inc. ("Zaxis"). Our principal executive offices are located at 3 Hanehoshet St, Building B, 7th floor, Tel Aviv, Israel 6971068. Our website address is <https://view-bix.com/> and our telephone number is + 972 9-774-1505.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 46.0						

Gross profitability		not computable	28.5%			latest aligned inputs end 2021-12-31; latest annual assets end 2025-12-31
Return on invested capital		(23.1%)	10.9%	89.6	136	2025-12-31
Accruals ratio		(100.9%)	(7.4%)	2.4	621	2025-12-31
Gross margin stability, five years		not computable	2.4 pts			five annual gross margins are required; found 3
Solvency, sleeve percentile 94.4						
Twelve-month failure probability		not computable	0.05%			liabilities and a nearby cover-page share count are required at 2026-06-30
Altman Z double-prime		not computable	2.18			latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31
Net debt to EBITDA		not computable	1.11x			EBITDA must exceed \$100,000
Interest coverage		not computable	3.77x			required facts have no common fiscal period end
Current ratio		0.41x	2.02x	94.4	666	2025-12-31
Growth and financing, sleeve percentile 98.6						
Revenue growth, three-year compound		not computable	6.4%			latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31
Free cash flow growth, three-year compound		not computable	17.2%			four consecutive annual FCF observations are required; found 5
Reinvestment rate		not computable	14.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		(44.7%)	5.0%	98.6	563	2025-12-31

Net share issuance, one year	not computable	0.5%	raw and split-adjusted prices do not align at 2025-03-20
------------------------------	----------------	------	--

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(65.9%)	2.2%	8
Distance from 52-week high	(72.8%)	(30.0%)	9
EBIT to enterprise value	(2.4%)	1.5%	26
Free cash flow yield	1.7%	2.7%	39
Book value to price	0.29	0.23	56
Sales to price	0.30	0.30	50
Composite equity issuance, five years	not computable	3.9%	
Relative strength against the sector, log excess return	(1.36)	(0.26)	8

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$2.4M
Operating cash flow, four quarters	-\$3.6M
Months of runway	8.1
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$215,199

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$41,000	2021-12-31	2022-03-17	10-K	0001493152-22-007150
2	assets	us-gaap:Assets	\$51.3M	2021-12-31	2023-03-24	10-K	0001493152-23-008765
3	operating income	us-gaap:OperatingIncomeLoss	-\$2.2M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$13.4M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$39,000	2025-12-31	2026-03-27	10-K	0001493152-26-013205
6	total debt	us-gaap:LongTermDebt	\$2.5M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
7	book equity	us-gaap:StockholdersEquity	\$5.0M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.0M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
9	total debt	us-gaap:LongTermDebt	\$6.6M	2024-12-31	2025-03-21	10-K	0001493152-25-011100
10	book equity	us-gaap:StockholdersEquity	\$5.8M	2024-12-31	2026-03-27	10-K	0001493152-26-013205

11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$24,000	2024-12-31	2026-03-27	10-K	0001493152-26-013205
12	net income	us-gaap:NetIncomeLoss	-\$19.3M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	\$2.8M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
14	assets	us-gaap:Assets	\$10.8M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
15	assets	us-gaap:Assets	\$22.0M	2024-12-31	2026-03-27	10-K	0001493152-26-013205
16	current assets	us-gaap:AssetsCurrent	\$153,000	2018-12-31	2020-03-20	10-K	0001493152-20-004372
17	current liabilities	us-gaap:LiabilitiesCurrent	\$833,000	2018-12-31	2020-03-20	10-K	0001493152-20-004372
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$13.6M	2018-12-31	2020-03-20	10-K	0001493152-20-004372
19	operating income	us-gaap:OperatingIncomeLoss	-\$578,000	2018-12-31	2020-03-20	10-K	0001493152-20-004372
20	book equity	us-gaap:StockholdersEquity	-\$721,000	2018-12-31	2021-03-16	10-K	0001493152-21-006123
21	assets	us-gaap:Assets	\$158,000	2018-12-31	2020-03-20	10-K	0001493152-20-004372
22	liabilities	us-gaap:Liabilities	\$975,153	2018-12-31	2019-03-29	10-K	0001493152-19-004164
23	depreciation amortization	us-gaap:Depreciation	\$67,000	2025-12-31	2026-03-27	10-K	0001493152-26-013205
24	current assets	us-gaap:AssetsCurrent	\$1.7M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
25	current liabilities	us-gaap:LiabilitiesCurrent	\$4.1M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$26.9M	2024-12-31	2025-03-21	10-K	0001493152-25-011100
27	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$79.6M	2023-12-31	2025-03-21	10-K	0001493152-25-011100
28	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$96.6M	2022-12-31	2024-03-25	10-K	0001493152-24-011132
29	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$45.2M	2021-12-31	2023-03-24	10-K	0001493152-23-008765
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1,000	2024-12-31	2025-03-21	10-K	0001493152-25-011100
31	depreciation amortization	us-gaap:Depreciation	\$115,000	2024-12-31	2026-03-27	10-K	0001493152-26-013205
32	operating income	us-gaap:OperatingIncomeLoss	-\$837,000	2024-12-31	2026-03-27	10-K	0001493152-26-013205
33	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$3.4M	2025-12-31	2026-03-27	10-K	0001493152-26-013205
34	income tax	us-gaap:IncomeTaxExpenseBenefit	\$131,000	2024-12-31	2026-03-27	10-K	0001493152-26-013205
35	current assets	us-gaap:AssetsCurrent	\$7.8M	2024-12-31	2026-03-27	10-K	0001493152-26-013205
36	current liabilities	us-gaap:LiabilitiesCurrent	\$12.9M	2024-12-31	2026-03-27	10-K	0001493152-26-013205
37	current assets	us-gaap:AssetsCurrent	\$17.8M	2023-12-31	2025-03-21	10-K	0001493152-25-011100
38	current liabilities	us-gaap:LiabilitiesCurrent	\$19.8M	2023-12-31	2025-03-21	10-K	0001493152-25-011100
39	assets	us-gaap:Assets	\$43.3M	2023-12-31	2025-03-21	10-K	0001493152-25-011100
40	assets	us-gaap:Assets	\$63.7M	2022-12-31	2024-03-25	10-K	0001493152-24-011132
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	13,336,392	2026-03-26	2026-03-27	10-K	0001493152-26-013205
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,296,945	2025-03-20	2025-03-21	10-K	0001493152-25-011100